Search Results | Blood | American Society of Hematology

1-20 of 806

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

DOI: https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Taking aim at IDH in fitter patients with AML

Andrew H. Wei, Naval Daver

Blood (2021) 137 (13): 1706–1707.

DOI: https://doi.org/10.1182/blood.2020009361

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

DOI: https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Diagnosing Absolute Iron-Deficiency Anemia in Patients on Hemodialysis in a Tertiary Care Centre: A Retrospective Chart Review

Robert C. Clayden, MSc, MD, Wilma Hopman, MSc, Frances Macleod, RN, David Good, MD FRCPC, Jocelyn Garland, MD FRCPC, Lawrence Hookey, MD FRCPC, Annette E. Hay

Blood (2019) 134 (Supplement_1): 4814.

DOI: https://doi.org/10.1182/blood-2019-129197

Published: 2019

Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4728.

DOI: https://doi.org/10.1182/blood-2019-123757

Published: 2019

Journal Articles

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Ersi Voskaridou, Mantzou Aimilia, PhD, Pagona Flevari, MD, Maria Dimopoulou, MD, Veroniki Komninaka, MD, Konstantina Repa, MD, Ioannis Papassotiriou, PhD

Blood (2019) 134 (Supplement_1): 4829.

DOI: https://doi.org/10.1182/blood-2019-122524

Published: 2019

Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1319.

DOI: https://doi.org/10.1182/blood-2019-131394

Published: 2019

Journal Articles

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

Wei Sang, MD, Ming Shi, Jingjing Yang, Jiang Cao, MD, Linyan Xu, PhD, Dongmei Yan, Xuguang Song, Cai Sun, Depeng Li, Feng Zhu, Zhenyu Li, MD, Junnian Zheng, Jianlin Qiao, PhD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 1590.

DOI: https://doi.org/10.1182/blood-2019-127640

Published: 2019

Journal Articles

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Naval G. Daver, MD, Kyoo Hyung Lee, MD PhD, Sung-Soo Yoon, MD PhD, Chul Won Jung, MD PhD, Hyun Jeong Kang, Sooa Jung, Sujin Seo, Jiyeon Yoon, Hyunjin Kim, Young Su Noh, Yoonha Seo, Hyeyoung Kwon, Oakpil Han, Seungjae Baek, MD PhD, Kyounghee Seo, Kwee Hyun Suh, PhD

Blood (2019) 134 (Supplement_1): 1331.

DOI: https://doi.org/10.1182/blood-2019-129670

Published: 2019

Journal Articles

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Fakiha Siddiqui, Emily Bontekoe, Darko Antic, PhD, Debra Hoppensteadt, PhD, Grigoris Gerotziafas, MD PhD, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 5239.

DOI: https://doi.org/10.1182/blood-2019-128440

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

DOI: https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

DOI: https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Blood (2019) 134 (Supplement_1): 840.

DOI: https://doi.org/10.1182/blood-2019-130009

Published: 2019

Journal Articles

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Blood (2019) 134 (Supplement_1): 1947.

DOI: https://doi.org/10.1182/blood-2019-126208

Published: 2019

Journal Articles

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Tony Zheng, Elizabeth R Lofurno, Sarah Elgamal, Alexander R Melrose, Jiaqing Pang, Joseph J Shatzel, MD, Owen J T McCarty, PhD, Joseph Aslan, PhD

Blood (2019) 134 (Supplement_1): 2074.

DOI: https://doi.org/10.1182/blood-2019-129066

Published: 2019

Journal Articles

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Odelia Amit, MD, Yael Bar-On, MD, Galit Perets, MD, Lena Atlas, Liat Shargian, MD, Moshe Yeshurun, MD, Bruria Yachini, RN, Chen Karni, RN, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 2018.

DOI: https://doi.org/10.1182/blood-2019-126999

Published: 2019

Journal Articles

Dominant Role of αIIbβ3 in Platelet Interactions with Polymerizing Cross-Linked Fibrin

Claudia Lorena Buitrago, PhD, Barry S. Coller, MD, Hina Zafar

Blood (2019) 134 (Supplement_1): 1061.

DOI: https://doi.org/10.1182/blood-2019-122753

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 823.

DOI: https://doi.org/10.1182/blood-2019-125136

Published: 2019

Journal Articles

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Iman Aboudalle, MD, Marina Y Konopleva, MD PhD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Kenneth Vaughan, RN, Mehmet Kurt, RN, Antonio Cavazos, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Lucia Masarova, MD, Musa E. Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 176.

DOI: https://doi.org/10.1182/blood-2019-121780

Published: 2019

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

DOI: https://doi.org/10.1182/blood-2019-124330

Published: 2019

2 3 4 5

NARROW

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Taking aim at IDH in fitter patients with AML

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Diagnosing Absolute Iron-Deficiency Anemia in Patients on Hemodialysis in a Tertiary Care Centre: A Retrospective Chart Review

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Dominant Role of αIIbβ3 in Platelet Interactions with Polymerizing Cross-Linked Fibrin

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only